Given that several further dual agonists are coming closer to becoming licenced, such as mazdutide and survodutide, with many more in development [15], combining licenced dual agonists with developing mono-agonists may be a faster way to develop effective treatments achieving triple agonism
Antoniv, L.V
Share your tracking data with your healthcare provider at each visit using patient portal uploads, printed summaries, or app reports
The compounded semaglutide with B12 injection makes it convenient to take both drugs together and ensures higher bioavailability than oral B12 supplements, avoiding gastrointestinal absorption issues
Insights from TRIUMPH-1 Phase 3 Trial On May 21, 2026, Eli Lilly released encouraging data from the TRIUMPH-1 Phase 3 trial, which examined retatrutide in obese or overweight individuals
1 The most common side effects affected the gut, as with other GLP-1 medications